DBV Technologies S.A. (DBVT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $18.89: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for... Read more
Sell if holding. Engine safety override at $18.89: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — DBV Technologies S.A.
Latest news
- Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target — benzinga May 4, 2026 positive
- Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55 — benzinga May 1, 2026 positive
- DBV Technologies Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $900.000K Miss $1.268M Estimate — benzinga Apr 30, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $18.89: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $17.89. Score 5.4/10, moderate confidence.
Take-profit target: $35.33 (+88.4% upside). Prior stop was $17.89. Stop-loss: $17.89.
Quality below floor (3.9 < 4.0).
DBV Technologies S.A. trades at a P/E of N/A (forward -38.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
8 analysts cover DBVT with a consensus score of 4.0/5. Average price target: $41.
What does DBV Technologies S.A. do?DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of...
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.